540 related articles for article (PubMed ID: 3978634)
1. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S
Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634
[TBL] [Abstract][Full Text] [Related]
2. Synergistic antitumor effects of BCG and monoclonal antibodies capable of inducing antibody-dependent cell-mediated cytotoxicity.
Komuta K; Kawase I; Ogura T; Masuno T; Yokota S; Hosoe S; Ikeda T; Shirasaka T; Kishimoto S
Jpn J Cancer Res; 1987 Feb; 78(2):185-92. PubMed ID: 3104261
[TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies directed to different tumor-associated antigens on a murine mammary tumor cell line, MM46.
Oshima H; Nishiya S
Jpn J Exp Med; 1987 Aug; 57(4):207-15. PubMed ID: 2448508
[TBL] [Abstract][Full Text] [Related]
5. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells.
Tsuchiya Y; Igarashi M; Suzuki R; Kumagai K
J Immunol; 1988 Jul; 141(2):699-708. PubMed ID: 2968407
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor effects of monoclonal antibodies with different immunoglobulin classes.
Seto M; Takahashi T; Nakamura S; Matsudaira Y; Nishizuka Y
Cancer Res; 1983 Oct; 43(10):4768-73. PubMed ID: 6192909
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
8. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
9. Differential antigenic expression of the DBA/2 lymphoma L1210 and its sublines: cross-reactivity with C3H mammary tumors as defined by syngeneic monoclonal antibodies.
Rapp L; Fuji H
Cancer Res; 1983 Jun; 43(6):2592-9. PubMed ID: 6342755
[TBL] [Abstract][Full Text] [Related]
10. Enhanced tumor growth and metastatic spread of an MH134 variant lacking a part of the MM antigen: a possible role of antibody-dependent cellular cytotoxicity in control of tumor growth and metastases.
Hara H; Kawase I; Komuta K; Masuno T; Kishimoto S
Int J Cancer; 1989 Jul; 44(1):137-42. PubMed ID: 2744883
[TBL] [Abstract][Full Text] [Related]
11. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
12. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation.
Johnson WJ; Steplewski Z; Matthews TJ; Hamilton TA; Koprowski H; Adams DO
J Immunol; 1986 Jun; 136(12):4704-13. PubMed ID: 3711663
[TBL] [Abstract][Full Text] [Related]
13. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
Masui H; Moroyama T; Mendelsohn J
Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
[TBL] [Abstract][Full Text] [Related]
15. Differential ability of tumor-unique and cross-reactive antigen(s) on two murine hepatoma cell lines to induce Lyt-1+2- T cells responsible for in vivo protective immunity.
Shima J; Yoshioka T; Kosugi A; Ogata M; Fujiwara H; Hamaoka T; Ueda S; Kato S
Biken J; 1987 Mar; 30(1):1-8. PubMed ID: 2445335
[TBL] [Abstract][Full Text] [Related]
16. Production of monoclonal antibodies against MM antigen: the serologic identification of MM antigen with Ly-6.2 alloantigen.
Seto M; Takahashi T; Tanimoto M; Nishizuka Y
J Immunol; 1982 Jan; 128(1):201-5. PubMed ID: 6976371
[TBL] [Abstract][Full Text] [Related]
17. Specific surface antigens expressed on activated mouse peritoneal macrophages and recognized by a novel monoclonal antibody.
Someya A
Immunology; 1985 Dec; 56(4):683-8. PubMed ID: 3908293
[TBL] [Abstract][Full Text] [Related]
18. Unusually efficient tumor cell lysis by human effectors of antibody-dependent cellular cytotoxicity mediated by monoclonal antibodies.
Christiaansen JE; Sears DW
Cancer Res; 1984 Sep; 44(9):3712-8. PubMed ID: 6744288
[TBL] [Abstract][Full Text] [Related]
19. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
